Journal
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
Volume 29, Issue 4, Pages 324-328Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.beha.2016.10.003
Keywords
Acute myeloid leukemia; AML; Phase 3; Primary refractory AML; Relapsed AML
Categories
Ask authors/readers for more resources
Fewer patients with primary refractory AML (PREF) are entered into phase 3 trials than are patients with relapsed AML This is particularly noteworthy because data from phase 3 trials for newly diagnosed AML indicated PREF and relapse are equally common. Here I discuss three possible reasons for this discrepancy. First, there is disagreement whether the criterion for PREF AML should be failure of one or two courses of initial induction therapy. Second, there may be an impression that PREF AML is qualitatively worse than relapsed AML. Third, there may be a general unwillingness to randomize patients with such poor prognoses. (C) 2016 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available